Compare Marriott International Inc (MAR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Marriott International Inc trades at $372.97 (market cap $96.87B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Marriott International Inc is far larger — about 19.9× Travere Therapeutics Inc. Common Stock's market cap, and Marriott International Inc pays a 0.79% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MAR | TVTX | |
|---|---|---|
Market Cap | $96.87B | $4.88B |
Volume | 755,878 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $67.52 |
52-Week Low | $259.04 | $26.79 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $114.19B | $5.01B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $371.82, up 0.68% today, near its resistance at $372. The stock shows bullish technical signals with strong moving averages, though the RSI indicates mild overbought conditions. Fundamentally, revenue grew to $26.19B in 2025 with a net income margin of 9.62%, but the P/E of 38.46 and P/B of 443.63 reflect premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share.
The outlook for MAR is positive, supported by robust travel demand and strategic initiatives like new technology partnerships. However, risks include high debt levels, with debt-to-asset ratio rising to 55.17% in 2024, and sensitivity to economic cycles. Analysts maintain a consensus price target of $388.93, suggesting moderate upside, but investors should weigh valuation concerns against growth prospects in the hospitality sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
